Aldosterone

An op-ed published in February by Tom Frieden, MD, MPH, former director of the CDC, described hypertension as “the deadliest but most neglected and widespread pandemic of our time” — and he’s right.

An experimental drug that inhibits aldosterone production reduced albuminuria in patients with chronic kidney disease, according to phase 2 study results published in The Lancet.

PHILADELPHIA — A novel aldosterone synthase inhibitor, BI 690517, was well-tolerated and reduced urine albumin-to-creatinine ratio in patients with chronic kidney disease, according to a presentation at ASN Kidney Week.

PHILADELPHIA — Obesity-associated dysregulated aldosterone is an endotype predictive of response to lorundrostat for patients with uncontrolled or treatment-resistant hypertension, according to data presented at ASN Kidney Week.

An investigational aldosterone synthase inhibitor was associated with clinically significant reductions in automated office BP for people with uncontrolled hypertension, with the greatest effects seen in people with concomitant obesity.

Efficacy and safety of multiple dose strengths of baxdrostat vs. placebo in treatment-resistant hypertension.

CHICAGO — Baxdrostat, an aldosterone synthase inhibitor, yielded substantial dose-related decreases in BP in patients with treatment-resistant hypertension, according to results from the phase 2 BrigHtn trial.

Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of end-stage kidney disease, according to data published in the European Heart Journal.

Mineralocorticoid receptor antagonists, particularly the most recently approved agent finerenone, should play a “central role” in the treatment of diabetic kidney disease and its related cardiovascular consequences, according to a speaker.

Galectin-3 interacted with risk for fatal CV events associated with aldosterone in patients referred for coronary angiography, according to a study published in The American Journal of Cardiology.